Who Paid My Doc
David Viskochil
Clinical Genetics (M.D.) Salt Lake City, UT Medical Doctor
NPI 1760561336 CMS profile 612747
100 Mario Capecchi Dr, Salt Lake City, UT 84113
General payments
$74,624
Research payments
$7,329
Ownership & investment interest
$0
Research they led as principal investigator
$1,490,806
Through program year 2025, David Viskochil of Salt Lake City, UT is reported in the CMS Open Payments database as having received $74,624 across 55 general payments and $7,329 in research payments paid to them. Separately, studies naming them as principal investigator received $1,490,806 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Clinical Genetics (M.D.) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,043 | 2 | |
| 2024 | General | $1,822 | 5 | |
| 2023 | General | $12,529 | 10 | |
| 2022 | General | $11,824 | 4 | |
| 2022 | Research | $1,250 | 1 | |
| 2021 | General | $3,000 | 1 | |
| 2020 | General | $11,004 | 12 | |
| 2020 | Research | $2,000 | 2 | |
| 2019 | General | $32,402 | 21 | |
| 2019 | Research | $4,079 | 5 |
Beside peers
- David Viskochil
- Clinical Genetics (M.D.) median
- Middle half of Clinical Genetics (M.D.)
- National median
In program year 2025, general payments to David Viskochil were reported at $2,043. Among 315 Clinical Genetics (M.D.) profiles paid that year, the median was $255 and the middle half received between $85 and $3,583.
Show as a table
| Year | David Viskochil | Clinical Genetics (M.D.) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $32,402 | $130 | $24–$2,691 | $163 |
| 2020 | $11,004 | $126 | $30–$3,700 | $114 |
| 2021 | $3,000 | $185 | $30–$3,777 | $132 |
| 2022 | $11,824 | $136 | $44–$2,749 | $149 |
| 2023 | $12,529 | $196 | $55–$5,220 | $160 |
| 2024 | $1,822 | $165 | $46–$3,171 | $164 |
| 2025 | $2,043 | $255 | $85–$3,583 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
63 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Genetics (M.D.) in Utah
Lorenzo Botto
Clinical Genetics (M.D.) · Salt Lake City, UT
John Carey
Clinical Genetics (M.D.) · Salt Lake City, UT
Vanina Taliercio
Clinical Genetics (M.D.) · Salt Lake City, UT
Douglas Ball
Clinical Genetics (M.D.) · Salt Lake City, UT
Ellen Arch
Clinical Genetics (M.D.) · St George, UT
Stacey Cole
Clinical Genetics (M.D.) · Salt Lake City, UT
Related records
Clinical Genetics (M.D.) in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Genetics (M.D.)
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.